Drug Search Results
More Filters [+]

Mavoglurant

Alternative Names: mavoglurant, afq056
Latest Update: 2024-11-27
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: MGLUR5 Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Mavoglurant

Countries in Clinic: United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Fragile X Syndrome

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

FX-LEARN

P2

Completed

Fragile X Syndrome

2022-05-17

Recent News Events